

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊 生物 科技 有限 公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Wai Chun Bio-Technology Limited (the “**Company**”) announces that, with effect from 14 February 2025, Ms. Kung Ying Tung (“**Ms. Kung**”) resigned as an independent non-executive Director (“**INED**”)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that Ms. Kung has tendered her resignation as an independent non-executive director, and will cease to act as the chairlady of the Company’s audit committee (the “**Audit Committee**”), a member of the Company’s remuneration committee (the “**Remuneration Committee**”) and a member of the Company’s nomination committee (the “**Nomination Committee**”) as she wished to devote more time to her personal commitments. Ms. Kung has confirmed that she has no disagreement with the Board and is not aware of any matters in connection with her resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited and the Shareholders.

NON-COMPLIANCE WITH REQUIREMENTS UNDER RULES 3.10(1), 3.10(2) AND 3.21 OF THE LISTING RULES

Pursuant to Rules 3.10(1) and 3.10(2) of the Listing Rules, every board of directors of a listed issuer must include at least three independent non-executive directors and at least one of the independent non-executive directors must have appropriate professional qualifications or accounting or related financial management expertise. Upon the resignation of Ms. Kung, no member of the Board possesses appropriate professional qualifications or accounting or related financial management expertise, and the number of INEDs is still less than three which is below the minimum requirement prescribed under Rules 3.10(1) of the Listing Rules.

Pursuant to Rule 3.21 of the Listing Rules, every listed issuer must establish an audit committee comprising non-executive directors only and the audit committee must comprise a minimum of three members and at least one of whom must be an independent non-executive director with appropriate professional qualifications or accounting or related financial management expertise as required under Rule 3.10(2) of the Listing Rules. Upon the resignation of Ms. Kung, the number of members of the audit committee of the Company is still less than three which is below the minimum requirement prescribed under Rule 3.21 of the Listing Rules and no member of the audit committee of the Company possesses appropriate professional qualifications or accounting or related financial management expertise.

To comply with Rules 3.10(1), 3.10(2) and 3.21 of the Listing Rules, the Company is in the process of identifying suitable candidate(s) to fill the vacancy and will continue to use its best endeavours to ensure that suitable candidate(s) is/are appointed as soon as practicable and in any event within three months from 14 February 2025 as required under Rule 3.11 of the Listing Rules.

By Order of the Board
Wai Chun Bio-Technology Limited
LAM Ka Chun
Executive Director

Hong Kong, 14 February 2025

As at the date of this announcement, the Board comprises one executive Director, namely Mr. Lam Ka Chun, and two independent non-executive Directors, namely Mr. Wan Bo and Mr. He Tao.